Jennison Associates LLC Invests $51.07 Million in Roivant Sciences Ltd. $ROIV

Key Points

• Jennison Associates LLC initiated a new position in Roivant Sciences, buying 2,353,386 shares worth about $51.07 million, equal to roughly 0.34% of the company.
• Significant insider and institutional activity: insiders have sold 5,085,398 shares (≈$139.2 million) in the past 90 days and now own 10.8%, while institutions hold 64.76% of the stock with large positions from Vanguard, UBS and others.
• Analyst sentiment and stock metrics: the consensus is a "Moderate Buy" (10 Buys, 1 Hold, 1 Sell) with a $30.55 target, and the shares trade around $28.53 (market cap ≈ $20.42B) with price targets as high as $40 from Piper Sandler.

Jennison Associates LLC bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 2,353,386 shares of the company's stock, valued at approximately $51,068,000. Jennison Associates LLC owned approximately 0.34% of Roivant Sciences as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of ROIV. Vanguard Group Inc. increased its stake in Roivant Sciences by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company's stock worth $912,681,000 after acquiring an additional 3,254,113 shares during the last quarter. Rubric Capital Management LP lifted its stake in shares of Roivant Sciences by 14.7% in the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company's stock valued at $229,574,000 after purchasing an additional 2,603,260 shares during the last quarter. State Street Corp boosted its holdings in shares of Roivant Sciences by 4.8% in the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company's stock worth $222,847,000 after purchasing an additional 911,827 shares during the period. UBS Group AG boosted its holdings in shares of Roivant Sciences by 570.0% in the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company's stock worth $399,080,000 after purchasing an additional 15,645,836 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of Roivant Sciences by 18.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 9,308,710 shares of the company's stock valued at $140,839,000 after purchasing an additional 1,423,074 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.

Roivant Sciences Trading Up 3.7%

Shares of Roivant Sciences stock opened at $28.53 on Friday. The stock's fifty day moving average price is $28.30 and its 200-day moving average price is $23.90. The firm has a market cap of $20.42 billion, a P/E ratio of -24.38 and a beta of 1.20. Roivant Sciences Ltd. has a 12 month low of $10.58 and a 12 month high of $30.33.

Insider Buying and Selling

In related news, insider Frank Torti sold 1,400,000 shares of the firm's stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $27.42, for a total transaction of $38,388,000.00. Following the sale, the insider owned 13,736,547 shares of the company's stock, valued at $376,656,118.74. This trade represents a 9.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $26.49, for a total value of $5,298,000.00. Following the completion of the transaction, the chief executive officer owned 1,654,597 shares in the company, valued at $43,830,274.53. This trade represents a 10.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 5,085,398 shares of company stock valued at $139,215,946 over the last ninety days. Company insiders own 10.80% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ROIV. TD Cowen reissued a "buy" rating on shares of Roivant Sciences in a research note on Wednesday, March 4th. Guggenheim lifted their price target on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday, February 9th. HC Wainwright upped their price target on shares of Roivant Sciences from $33.00 to $34.00 and gave the company a "buy" rating in a report on Wednesday, March 4th. Piper Sandler raised their price objective on shares of Roivant Sciences from $22.00 to $40.00 and gave the stock an "overweight" rating in a research note on Thursday, April 16th. Finally, Citigroup boosted their target price on Roivant Sciences from $26.00 to $35.00 and gave the company a "buy" rating in a research report on Tuesday, February 10th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $30.55.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.